Following Australia's Therpaeutic Goods Administration approval of Afluria Quad (PD 01 Aug 16), the US Food and Drug Administration (FDA) has now approved the quadrivalent influenza vaccine from Seqirus, CSL's vaccine company.
It is the second quadrivalent influenza vaccine that Seqirus is offering this season after the FDA approved Flucelvax Quadrivalent influenza vaccine in May.
Afluria Quadrivalent comes in single-dose, preservative-free prefilled syringes whereas the trivalent Afluria is available in prefilled syringes and multidose vials and is the only flu vaccine approved for needle-free administration; the vaccine is delivered through a narrow stream of fluid directly into the skin in about one tenth of a second.
The above article was sent to subscribers in Pharmacy Daily's issue from 31 Aug 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 31 Aug 16